Cutaneous adverse events following treatment with third-generation EGFR tyrosine kinase inhibitors

被引：0
|
作者：
Li Pomi, Federica [1 ]
Vaccaro, Federico [2 ]
Borgia, Francesco [1 ]
Irrera, Natasha [1 ]
Vaccaro, Mario [1 ]
机构：
[1] Univ Messina, Dept Clin & Expt Med, Sect Dermatol, I-98125 Messina, Italy
[2] Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy
来源：
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 159卷 / 02期
关键词：
D O I：
10.23736/S2784-8671.23.07781-2
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：212 / 214
页数：3
相关论文
共 50 条
  • [1] Update on third-generation EGFR tyrosine kinase inhibitors
    Gray, Jhanelle
    Haura, Eric
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 360 - 362
  • [2] Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
    Shuhang Wang
    Yongping Song
    Feifei Yan
    Delong Liu
    Frontiers of Medicine, 2016, 10 (04) : 383 - 388
  • [3] Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
    Shuhang Wang
    Yongping Song
    Feifei Yan
    Delong Liu
    Frontiers of Medicine, 2016, 10 : 383 - 388
  • [4] Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
    Wang, Shuhang
    Song, Yongping
    Yan, Feifei
    Liu, Delong
    FRONTIERS OF MEDICINE, 2016, 10 (04) : 383 - 388
  • [5] The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
    Wang, Fen
    Zhou, Qing
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 481 - 486
  • [6] Third-Generation Tyrosine Kinase Inhibitors and Beyond
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Cortes, Jorge
    SEMINARS IN HEMATOLOGY, 2010, 47 (04) : 371 - 380
  • [7] Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR plus NSCLC
    Nagasaka, Misako
    Zhu, Viola W.
    Lim, Sun Min
    Greco, Michael
    Wu, Fengying
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (05) : 740 - 763
  • [8] Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer
    Murtuza, Ayesha
    Bulbul, Ajaz
    Shen, John Paul
    Keshavarzian, Parissa
    Woodward, Brian D.
    Lopez-Diaz, Fernando J.
    Lippman, Scott M.
    Husain, Hatim
    CANCER RESEARCH, 2019, 79 (04) : 689 - 698
  • [9] Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy
    Oiki, H.
    Suda, K.
    Hamada, A.
    Obata, K.
    Sakai, K.
    Fujino, T.
    Fukuda, S.
    Ohara, S.
    Ito, M.
    Soh, J.
    Nishio, K.
    Mitsudomi, T.
    Tsutani, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S312 - S312
  • [10] What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors
    Laface, Carmelo
    Fedele, Palma
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 220 - 222
12345